day 1 agenda
| 7th Edition of Innovations and State of the Art in | |
| ALZHEIMER'S & DEMENTIA | |
| on Sep 07-08, 2026 at Paris, France | |
| Day -1(Sep 07, 2026) | |
| Keynote Sessions | |
| 09:00-09:30 | KeynoteTalk: Genetic Therapies for APOE4-Associated Alzheimer’s Diseases |
| Ronald Crystal, Weill Cornell Medicine, USA | |
| 09:30-10:00 | KeynoteTalk: ACE-dependent Alzheimer’s disease (AD) |
| Sergei M. Danilov, University of Illinois, USA | |
| 10:00-10:30 | KeynoteTalk: Glomerular (mesangial) amyloidogenesis in AL (light chain-associated) amyloidosis: Translational studies with implications for further treatment modalities. Similarities with amyloid formation in Alzheimer disease |
| Guillermo A. Herrera, University of South Alabama, USA | |
| Group Photo & Refreshment Break (10:30-10:50) | |
| Technical session-I | |
| Advances in Alzheimer’s and Dementia Research & Neurodegenerative Diseases |
|
| 10:50-11:10 | Relationships among tau, amyloid, neuroinflammation, NMDA receptors and cognitive performance are strongly modulated by sex |
| Anat Biegon, University of Uppsala, Sweden | |
| 11:10-11:30 | Imaging oxidative stress in neurodegenerative disorders with Positron Emission Tomography with [18F]ROStrace |
| Robert H. Mach, University of Pennsylvania, USA | |
| 11:30-11:50 | Slot Available |
| 11:50-12:10 | Moderate-Severe Traumatic Brain Injury May Cause Neurodegeneration in the Early and Late Chronic Stages of Injury |
| Robin Green , University of Toronto, Canada | |
| 12:10-12:30 | Intermittent hypoxia training attenuates brain atrophy in elderly adultswith mild cognitive impairment |
| Xiangrong Shi, University of North Texas Health Science Centre, USA | |
| 12:30-12:50 | Cortical neuron dysfunction in AD brain at early-stage without beta-amyloid aggregation |
| Xiu-Ti Hu, Rush University Medical Center, USA | |
| 12:50-13:10 | Slot Available |
| Lunch Break @ Restaurant (13:10-14:00) | |
| 14:00-14:20 | The Enigma of Brain Iron: From Brain Iron Overload to Functional Iron Deficiency in Neurodegenerative Diseases |
| Levi Sonia, University Vita-Salute San Raffaele , Italy | |
| 14:20-14:40 | Nonhuman Primate Models of Alzheimer’s Disease And Parkinson’sDisease Co-pathologies |
| Jeffrey H. Kordower, Arizona State University, USA | |
| 14:40-15:00 | Slot Available |
| Technical session-II | |
| Dementia diagnosis, treatment | |
| & | |
| Vascular Dementia, Aging and Dementia, Risk reduction and prevention | |
| 15:00-15:30 | Plenary Talk: Digital Twins in Clinical Trials for Alzheimer’s Disease |
| Irfan Chaudhuri, Harvard University, USA | |
| 15:30-15:50 | The Traumatic brain injury and the risk of dementia |
| Wendy Lin, University of British Columbia, Canada | |
| 15:50-16:10 | Arterial Tortuosity as a Marker of Cerebrovascular Aging and Dementia Risk |
| Yulin Ge, NYU Grossman School of Medicine, USA | |
| 16:10-16:30 | Slot Available |
| 16:30-16:50 | Stepwise identification of prodromal dementia: testing a practical model for primary care |
| Boaz Levy, University of Massachusetts Boston, USA | |
| Refreshment Break(16:50-17:10) | |
| Note: This is a Tentative program, subjects and timings will changes. | |
| Day-1 Concludes | |
day 2 agenda
| Day -2(Sep 08, 2026) | |
| Keynote Sessions | |
| 09:00-09:30 | KeynoteTalk: GABA-A receptor modulating steroids enhance dementia, but antagonists inhibit inflammation and improve memory |
| Torbjörn Bäckström, Umeå University, Sweden | |
| 09:30-10:00 | Slot Available |
| 10:00-10:30 | KeynoteTalk: Acetylcholinesterase inhibitors have anti- neurodegenerative benefits, but high-level CNS-selective acetylcholinesterase inhibition is needed for delaying the onset or preventing Alzheimer’s dementia |
| Donald E. Moss, University of Texas at El Paso, USA | |
| Group Photo & Refreshment Break (10:30-10:50) | |
| Technical session-III | |
| Biomarkers for AD and Dementia, Basic and Translational Research & Genetics in Alzheimer’s and Dementia, Molecular and Cell Biology, Data Science and Artificial Intelligence |
|
| 10:50-11:10 | Long read sequencing in alzheimer’s disease and cerebral amyloid angiopathy |
| Amanda J. Myers, University of Miami, USA | |
| 11:10-11:30 | From Cost-Effective Plasma Biomarker Quantification to Cross-Cohort Machine Learning Translation in Alzheimer’s Disease |
| Ebrahim Zandi, University of Southern California, USA | |
| 11:30-11:50 | Towards a panel of seed amplification assays for the detection of protein pathologies in the CSF of living patients with dementia |
| Magnus Macleod, University College London, UK | |
| 11:50-12:10 | Slot Available |
| 12:10-12:30 | Exploring the role of Aβ-induced membrane damage in tau pathology |
| Katherine R. Sadleir, , Northwestern University, USA | |
| 12:30-12:50 | Development and Validation of Patient and Caregiver-Reported Outcome Measures for Alzheimer’s Disease, Mild Cognitive Impairment, and Dementia: The CI-HI & CICR-HI |
| Charlotte Engebrecht, University of Rochester Center for Health + Technology, USA | |
| 12:50-13:10 | Obtaining personalized predictions from a randomized controlled trial on Alzheimer’s disease |
| Dennis Shen, University of Southern California, USA | |
| 13:10-13:30 | Beyond Plaques and Tangles: Visualizing Early Oxidative Stress in Alzheimer's Disease via a Novel Radiotracer |
| Meagan J McManus, University of Arizona, USA | |
| Lunch Break @ Restaurant (13:30-14:10) | |
| Technical Session IV – To Be Announced Soon The agenda for Technical Session IV is currently being finalized as abstract submissions are still being received and reviewed by our Scientific Committee. The updated session details will be published shortly. |
|
posters agenda
| Day -1(Sep 07, 2026) | |
| Virtual Tentative Program followed by CET | |
| 10:00-10:20 | 6-microRNA panel predicts amyloid-b status in cognitively normal older adults |
| Joanna M. Williams, University of Otago, NewZealand | |
| 10:20-10:40 | Development of amyloid β (1-42) certified reference material NMIJ CRM 6210-a |
| Kazumi Saikusa, National Metrology Institute of Japan (NMIJ), Japan | |
| 10:40-11:00 | Slot Available |
| 11:00-11:20 | Huntingtin’s N17 region: Post-translational modifications as modulators of protein self-association and membrane interaction |
| Mariana Gallo, University of Parma, Italy | |
| 11:20-11:50 | Keynote Talk: NAP, the investigational drug davunetide, from laboratory discovery to sex-specific cognitive protection in clinical trials |
| Illana Gozes, Tel Aviv University, Israel | |
| 11:50-12:10 | Selective manipulation of aging as a novel treatment for neurodegenerative disorders |
| Ehud Cohen, The Hebrew University School of Medicine, Israel | |
| 12:10-12:30 | Slot Available |
| 12:30-12:50 | Early Linguistic Indicators and Language-Focused Therapies in Alzheimer’s Disease |
| Erika Smeriglio, University of Messina, Italy | |
| 12:50-13:10 | Slot Available |
| 13:10-13:30 | Correction of the APP London (V717I) mutation using an optimized prime editing system. |
| Jacques P. Tremblay, Université Laval, Canada | |
| 13:30-13:50 | Methionine-sulfoxide based active immunization against Alzheimer’s disease |
| Jackob Moskovitz, University of Kansas, USA | |
| 13:50-14:20 | Keynote Talk: Elovanoids: linking nutrition to neuroprotection |
| Nicolas G. Bazan, Neuroscience Center of Excellence, USA | |
| 14:20-14:40 | Spiritual Fitness: The New Dimension In Alzheimer’s Disease Prevention |
| Eve Adler, Alzheimer's Research and Prevention Foundation, USA | |
| 14:40-15:00 | The importance of social relationships in place in Alzheimer’s Disease |
| George Rook, a person living with dementia and co-researcher on several projects, USA | |
| 15:00-15:20 | Slot Available |
| 15:20-15:40 | Establishing two-tier cutoffs for ptau217/A42 ratio in plasma for detection of Alzheimers disease pathology |
| Leslie M Shaw, University of Pennsylvania, USA | |
| 15:40-16:00 | Air pollution risk of Alzheimer in a mouse model of amyloidogenesis is attenuated by modulation of gamma-secretase |
| Caleb E Finch, University of Southern California, USA | |
| Day-1 Concludes | |
| Day -2(Sep 08, 2026) | |
| Virtual Tentative Program followed by CET | |
| 10:00-10:20 | Cultural Perspectives on Virtual delivery of Cognitive Stimulation Therapy for M?ori with Dementia (vCST-M?ori) |
| Tai Kake, University of Auckland, NewZealand | |
| 10:20-10:40 | The therapeutic potential of medicinal cannabis for neurodegenerative diseases – a preclinical perspective |
| Tim Karl, Western Sydney University, Australia | |
| 10:40-11:00 | Slot Available |
| 11:00-11:20 | Revitalizing Mitochondria against Alzheimer’s disease: The Synergistic Effects of a Nutraceutical Combination with urolithin A |
| Dona Pamoda W. Jayatunga, University of Sri Jayewardenepura, Sri Lanka | |
| 11:20-11:50 | Keynote Talk: Restoring neuronal function by restoring the septin cytoskeleton |
| Gerard Griffioen, remynd, Belgium | |
| 11:50-12:10 | Targeting the GSK3β/Nav1.6 protein–protein interaction offers a promising new therapeutic approach for early-stage Alzheimer’s disease |
| Fernanda Laezza, University of Texas Medical Branch, USA | |
| 12:10-12:30 | Non-catalyzed covalent dimerization of amyloid b and implications for Alzheimer’s disease |
| Suren A. Tatulian, University of Central Florida, USA | |
| 12:30-12:50 | Protein disulfide isomerase dissolves and detoxifies oligomeric assemblies of amyloid beta peptide |
| Ken Teter, University of Central Florida, USA | |
| 12:50-13:10 | Molecular Mechanisms Underlying the Inverse Roles of Heme Function in Lung Cancer and Alzheimer’s Disease |
| Li Zhang, University of Texas at Dallas, USA | |
| 13:10-13:30 | Slot Available |
| 13:30-13:50 | Alzheimer’s Is Dynamic – Our Language Has Not Kept Pace: Redefining Diagnosis Through Precision and Human-Centered Staging |
| Lauren P. Brown, The Alzheimer's Experience, USA | |
| 13:50-14:20 | Keynote Talk: Systems Thinking |
| Michael Fossel, Michigan State University, USA | |
| 14:20-14:40 | Identification of novel shared antibodies and infectious disease associations in Alzheimer’s disease |
| Mark Hicar, University at Buffalo, USA | |
| 14:40-15:00 | Slot Available |
| 15:00-15:20 | Asymmetric Cerebral Hypoperfusion Drives Regional Blood Brain Barrier Permeability in a Vascular Dementia Model |
| Zhen Xu, The University of Texas Health Science Center at Houston, USA | |
The program for this session is currently being updated to accommodate recently received abstracts and ongoing scientific scheduling.
Full session details will be announced soon.